{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:00:20Z","timestamp":1777143620849,"version":"3.51.4"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/ftd.0b013e31825a4c3a","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T08:54:15Z","timestamp":1338540855000},"page":"381-389","source":"Crossref","is-referenced-by-count":38,"title":["Critical Illness Is a Major Determinant of Midazolam Clearance in Children Aged 1 Month to 17 Years"],"prefix":"10.1097","volume":"34","author":[{"given":"Ibrahim","family":"Ince","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariska Y.M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl J.","family":"Murry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Tibboel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherijne A.J.","family":"Knibbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-5-20210129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":". Cytochrome P450 3A: ontogeny and drug disposition.","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"R2-5-20210129","first-page":"220","article-title":"Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes Curr Opin Pediatr.","volume":"7","author":"Kearns","year":"1995","journal-title":""},{"key":"R3-5-20210129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/106002809603000104","article-title":". Steady-state plasma concentrations of midazolam in critically ill infants and children.","volume":"30","author":"Hughes","year":"1996","journal-title":"Ann Pharmacother"},{"key":"R4-5-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0300-483X(95)03155-9","article-title":"Substrates of human hepatic cytochrome P450 3A4.","volume":"104","author":"Li","year":"1995","journal-title":"Toxicology"},{"key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00679782","article-title":". The pharmacokinetics of midazolam in paediatric patients.","volume":"37","author":"Payne","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1097\/01.ccm.0000084806.15352.da","article-title":". Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.","volume":"31","author":"de Wildt","year":"2003","journal-title":"Crit Care Med"},{"key":"R7-5-20210129","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/00000542-200612000-00013","article-title":". Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery.","volume":"105","author":"Peeters","year":"2006","journal-title":"Anesthesiology"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00134-003-1758-3","article-title":". Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.","volume":"29","author":"Carcillo","year":"2003","journal-title":"Intensive Care Med"},{"key":"R10-5-20210129","first-page":"104","article-title":"Riva L, van den Anker JN, et al..","volume":"67","author":"de Wildt","year":"2000","journal-title":"Does age alter the pharmacokinetics of midazolam and l-OH-midazolam in paediatric patients Clin Pharmacol Ther"},{"key":"R12-5-20210129","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics.","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11095-010-0333-1","article-title":". Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models.","volume":"28","author":"Krekels","year":"2011","journal-title":"Pharm Res"},{"key":"R15-5-20210129","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270003253624","article-title":". Model appropriateness and population pharmacokinetic modeling.","volume":"43","author":"Ette","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","article-title":". Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.","volume":"23","author":"Brendel","year":"2006","journal-title":"Pharm Res"},{"key":"R17-5-20210129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00007691-200502000-00018","article-title":". Pharmacodynamics of midazolam in pediatric intensive care patients.","volume":"27","author":"de Wildt","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R18-5-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00003246-198211000-00001","article-title":". Changes in hepatic flow induced by continuous positive pressure ventilation in critically ill patients.","volume":"10","author":"Bonnet","year":"1982","journal-title":"Crit Care Med"},{"key":"R19-5-20210129","first-page":"69","article-title":". Splanchnic and total body oxygen consumption differences in septic and injured patients.","volume":"101","author":"Dahn","year":"1987","journal-title":"Surgery"},{"key":"R20-5-20210129","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/bja\/61.3.302","article-title":". A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery.","volume":"61","author":"Mathews","year":"1988","journal-title":"Br J Anaesth"},{"key":"R21-5-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2044.1996.tb07646.x","article-title":"What changes drug metabolism in critically ill patientsII Serum inhibits the metabolism of midazolam in human microsomes.","volume":"51","author":"Park","year":"1996","journal-title":"Anaesthesia"},{"key":"R22-5-20210129","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2044.1987.tb03086.x","article-title":"Failure of critically ill patients to metabolise midazolam.","volume":"42","author":"Shelly","year":"1987","journal-title":"Anaesthesia"},{"key":"R23-5-20210129","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bcp.2004.11.025","article-title":"Repression of PXR-mediated induction of hepatic CYP3A gene expression by protein kinase C.","volume":"69","author":"Ding","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"R24-5-20210129","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection.","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab Rev"},{"key":"R25-5-20210129","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.1840170212","article-title":"Interferon suppresses erythromycin metabolism in rats and human subjects.","volume":"17","author":"Craig","year":"1993","journal-title":"Hepatology"},{"key":"R26-5-20210129","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/01.CCM.0000063040.24541.49","article-title":". Cytochrome P450 3A4 activity after surgical stress.","volume":"31","author":"Haas","year":"2003","journal-title":"Crit Care Med"},{"key":"R27-5-20210129","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17425255.4.2.137","article-title":". Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.","volume":"4","author":"Kacevska","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R28-5-20210129","first-page":"1202","article-title":". Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices.","volume":"28","author":"Renwick","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R29-5-20210129","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","article-title":". Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R30-5-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jss.2010.06.040","article-title":". Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model.","volume":"167","author":"Kumar","year":"2011","journal-title":"J Surg Res"},{"key":"R31-5-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF03005352","article-title":"Craniosynostosis: an assessment of blood loss and transfusion practices.","volume":"36","author":"Kearney","year":"1989","journal-title":"Can J Anaesth"},{"key":"R32-5-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/bja\/85.4.599","article-title":"The role of albumin in critical illness.","volume":"85","author":"Nicholson","year":"2000","journal-title":"Br J Anaesth"},{"issue":"suppl 1","key":"R33-5-20210129","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1111\/j.1365-2125.1983.tb02270.x","article-title":"Pharmacokinetics and bioavailability of midazolam in man.","volume":"16","author":"Heizmann","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"R34-5-20210129","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1460-9592.2010.03364.x","article-title":"A maturation model for midazolam clearance.","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr Anaesth"},{"key":"R35-5-20210129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R36-5-20210129","first-page":"1","article-title":"Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods Clin Pharmacokinet.","volume":"45","author":"Bjorkman","year":"2006","journal-title":""},{"key":"R37-5-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00003088-200948060-00003","article-title":". Morphine glucuronidation in preterm neonates, infants and children younger than 3 years.","volume":"48","author":"Knibbe","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"R38-5-20210129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1651-2227.2006.00156.x","article-title":"DA, van der Werff SD, Sibarani-Ponsen R, et al.. Age is of influence on midazolam requirements in a paediatric intensive care unit.","volume":"96","year":"2007","journal-title":"Acta Paediatr"},{"key":"R39-5-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2165\/00003088-199426040-00005","article-title":"Lean body mass as a predictor of drug dosage. Implications for drug therapy.","volume":"26","author":"Morgan","year":"1994","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31825a4c3a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:43Z","timestamp":1620952783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201208000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31825a4c3a","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}